SOFPOG ORGANISES CPD ON “ACHIEVING UNIVERSAL HEALTHCOVERAGE THROUGH EARLY DETECTION AND MANAGEMENT OF NON-COMMUNICABLE DISEASES
The First in a series of CPDs organized by SOFPOG to commemorate the 2023 World Family Doctor Day and 9th AGSM was held on Wednesday 10th May 2023 at 3pm.
It was on the theme “Achieving Universal Health Coverage through early detection and management of non-communicable diseases.”
It was a hybrid event held virtually via zoom and in-person at the Ghana College of Physicians and Surgeons.
The speakers were Prof Akye Essuman, Faculty Chair , Family Medicine and Lecturer at UHAS, Ho and Dr Francis Addai, A Family Physician Specialist and Diabetologist at Focos Orthopedic Hospital.
Prof Essuman, spoke on the topic, Patient-centered approach to care of patients with chronic illness.
He made it known that Family Physicians lead the way in Patient Centred Clinical (PCC) Model by way of their training, practice and advocacy. They were also tasked to train others in healthcare about PCC, policy framers were encouraged to incorporate PCC in management of NCDs, development or adaptation of PCC models should be relevant to our context and an enabling environment should be provided to healthcare providers to support the practice of PCC
Dr Addai spoke on the topic, Current trends in the management of Diabetes. During His presentation, he said that Cardiovascular risk reduction is now possible with anti-diabetes medications. Clinicians need to apply new data from research to patient populations that can derive benefits. He further stated that Initiating SGLT2i/GLP1-RA in a higher-risk patient is certainly compelling based on available data and They are indicated to reduce risk for CV death in patients with Type 2 Diabetes Mellitus and established Cardiovascular Disease. Empagliflozin and Canagliflozin are FDA-indicated to reduce the risk of MACE in adult with T2D and established CVD. Evidence modestly stronger for Empa > Cana in ADA-EASD consensus report. All SGLT2i have shown reduction in HHF and CKD progression in Cardiovascular outcome Trials.
There were presentations from our sponsors NOVONORDISK and Boehringer Ingelheim . Novonordisk presented on Insulin Degludec and Boehringer Ingelheim presented on Hypoglycemia and Empaglifozin ( Jardiance) .
A total of about 820 participants took part in this CPD virtually and in-person.
The program was moderated by Dr George Bediako Nketiah, President of SOFPOG.
